IDEXX LABORATORIES INC /DE

Form 4 May 11, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person * **AYERS JONATHAN W**

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

IDEXX LABORATORIES INC /DE

(Check all applicable)

[IDXX]

(First) (Middle)

(Street)

3. Date of Earliest Transaction (Month/Day/Year)

X Director 10% Owner Other (specify X_ Officer (give title

05/10/2017

below)

ONE IDEXX DRIVE

Chairman, President & CEO 6. Individual or Joint/Group Filing(Check

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

WESTBROOK, ME 04092

| | | Telson | | | | | | | |
|--------------------------------------|---|--|-----------------|--|-----|-----------------------|--|--|---|
| (City) | (State) | (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Code (Instr. 8) | TransactiorDisposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock | 05/10/2017 | | Code V M | Amount 10,000 | (D) | Price \$ 38.795 | 1,024,994 | D | |
| Common Stock | 05/10/2017 | | S | 10,000 | D | \$ 162.3092 (1) | 1,014,994 | D | |
| Common Stock | 05/10/2017 | | M | 20,000 | A | \$ 38.795 | 1,034,994 | D | |
| Common Stock | 05/10/2017 | | S | 6,200 | D | \$ 162.283 (2) | 1,028,794 | D | |
| Common Stock | 05/10/2017 | | S | 10,800 | D | \$ 163.276 (3) | 1,014,994 | D | |

Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

Common Stock 98,000 I by Ayers Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactic Code (Instr. 8) | 5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amour Underlying Securit (Instr. 3 and 4) | |
|---|---|---|---|--|---|--|--------------------|--|---------------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amo or Num of Sh |
| Non-Qualified Stock Option (right-to-buy) | \$ 38.795 | 05/10/2017 | | M | 10,000 | <u>(4)</u> | 02/13/2018 | Common Stock | 10,0 |
| Non-Qualified Stock Option (right-to-buy) | \$ 38.795 | 05/10/2017 | | M | 20,000 | (5) | 02/13/2018 | Common Stock | 20,0 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--------------------------------|---------------|-----------|---------------------------|-------|--|--|--|
| 1 8 | Director | 10% Owner | Officer | Other | | | |
| AYERS JONATHAN W | | | | | | | |
| ONE IDEXX DRIVE | X | | Chairman, President & CEO | | | | |
| WESTBROOK, ME 04092 | | | | | | | |

Signatures

/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers 05/11/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

- Represents the weighted average sales price of the shares sold ranging from a low of \$161.55 to a high of \$162.50 per share. The (1) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of \$161.95 to a high of \$162.90 per share. The (2) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of \$163.04 to a high of \$163.60 per share. The (3) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
 - Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016 without giving effect to
- (4) the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual (5) installments beginning on February 14, 2012 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- (6) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.